Bayer's Appeal Of India CL For Nexavar Enters Final Hearing Stage
This article was originally published in PharmAsia News
Executive Summary
Final hearings have begun in India into Bayer's appeal of the first compulsory licensing of a pharmaceutical product, granted last year to Natco for its generic of Nexavar (sorafenib).